A rapid method for analyzing serum pro-insulin-like growth factor-II in patients with non-islet cell tumor hypoglycemia.
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
CONTEXT: Non-islet cell tumor hypoglycemia (NICTH) results from the hypersecretion of pro-IGF-II by a large, usually mesenchymal tumor. Detection of pro-IGF-II in serum is a potential tumor marker in these patients. OBJECTIVE: The aim of this study was to validate a rapid and reliable method for determining serum pro-IGF-II. PATIENTS: Serum samples from 16 patients with NICTH were studied. MAIN OUTCOME MEASURE: The main outcome measure was serum concentration of pro-IGF-II determined by immunoblot analysis of pro-IGF-II and mature IGF-II after 16.5% tricine-SDS-PAGE, which was compared with pro-IGF-II measured by standard RIA after size-exclusion acid chromatography. RESULTS: The analyses of patients' sera by size-exclusion acid chromatography showed that 68 +/- 19% of IGF-II were present in the pro-IGF-II form, whereas only 18 +/- 4% corresponded to pro-IGF-II in controls. Scanning densitometry of immunoblots showed 67 +/- 16% in the bands corresponding to pro-IGF-II in patients' sera, compared with 27 +/- 9% in controls. The detection sensitivity of tricine-SDS-PAGE method was the same as for size-exclusion chromatography, but the tricine-SDS-PAGE method is quicker and requires smaller amounts of serum. CONCLUSION: Tricine-SDS-PAGE followed by IGF-II immunoblot analysis provides a rapid, reproducible, and sensitive method for the separation of serum pro-IGF-II from mature IGF-II and is a useful laboratory evaluation of patients with a clinical diagnosis of NICTH.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The total level of IGF-II may be normal, but the ratio of pro-IGF-II to IGF-II may be elevated; this can be demonstrated by chromatographic techniques, most easily and rapidly using thin layer chromatography (29).”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [29]
Citations
Cites
Schägger, H., & von Jagow, G. (1987) · Analytical Biochemistry · doi:10.1016/0003-2697(87)90587-2 · Cited by 11,444
Comparing methods of measurement: why plotting difference against standard method is misleading
Bland, J. M., & Altman, D. G. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91748-9 · Cited by 2,343
Insulin-like growth factors I and II in healthy man.
Guler, H.-P., Zapf, J., Schmid, C., & Froesch, E. R. (1989) · Acta Endocrinologica · doi:10.1530/acta.0.1210753 · Cited by 531
Daughaday, W. H., Emanuele, M. A., Brooks, M. H., Barbato, A. L., Kapadia, M., & Rotwein, P. (1988) · New England Journal of Medicine · doi:10.1056/nejm198812013192202 · Cited by 351
Sequence of a cDNA clone encoding human preproinsulin-like growth factor II
Bell, G. I., Merryweather, J. P., Sanchez-Pescador, R., Stempien, M. M., Priestley, L., Scott, J., & Rall, L. B. (1984) · Nature · doi:10.1038/310775a0 · Cited by 321
Sleep apnoea and nocturnal angina
Franklin, K. A., Sahlin, C., Nilsson, J. B., & Näslund, U. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90820-x · Cited by 308
Zapf, J., Futo, E., Peter, M., & Froesch, E. R. (1992) · Journal of Clinical Investigation · doi:10.1172/jci116152 · Cited by 172
Davenport, M. L., CLEMMONS, D. R., Miles, M. V., Camacho‐Hübner, C., D’ERCOLE, A. J., & UNDERWOOD, L. E. (1990) · Endocrinology · doi:10.1210/endo-127-3-1278 · Cited by 154
Daughaday, W. H., & Kapadia, M. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.17.6778 · Cited by 136
Baxter, R. C. (1995) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.80.9.2700 · Cited by 127
Cited by
Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)
Thakker, R. V., Newey, P. J., Walls, G. V., Bilezikian, J., Dralle, H., Ebeling, P. R., Melmed, S., Sakurai, A., Tonelli, F., & Brandi, M. L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1230 · Cited by 1,477
Francis, G. L., Waguespack, S. G., Bauer, A. J., Angelos, P., Benvenga, S., Cerutti, J. M., Dinauer, C. A., Hamilton, J., Hay, I. D., Luster, M., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0460 · Cited by 1,238
Cryer, P. E., Axelrod, L., Grossman, A. B., Heller, S. R., Montori, V. M., Seaquist, E. R., & Service, F. J. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1410 · Cited by 1,277
Self-citationDynkevich, Y., Rother, K. I., Whitford, I., Qureshi, S., Galiveeti, S., Szulc, A. L., Danoff, A., Breen, T. L., Kaviani, N., Shanik, M. H., et al. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1033 · Cited by 224
“Most recently, a more rapid assay has been developed that employs thin layer chromatography (109).”
MethodManagement of Non-Islet-Cell Tumor Hypoglycemia: A Clinical Review
Bodnar, T. W., Acevedo, M. J., & Pietropaolo, M. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3382 · Cited by 217
“raki-Moud et al (15) published 16 cases.”
MethodInfluentialNon-Islet Cell Tumour-Induced Hypoglycaemia: A Review of the Literature Including Two New Cases
de Groot, J. W. B., Rikhof, B., van Doorn, J., Bilo, H. J. G., Alleman, M. A., Honkoop, A. H., & van der Graaf, W. T. A. (2007) · Endocrine Related Cancer · doi:10.1677/erc-07-0161 · Cited by 222
“…and mature IGF-II after 16.5% tricinesodium dodecyl sulphate–polyacrylamide gels has proven to be a more rapid, reproducible and equally sensitive method and a useful laboratory evaluation www.endocrinology-journals.org of patients with a clinical diagnosis of NICTH (Miraki-Moud et al. 2005).”
BackgroundMethodInfluentialMANAGEMENT OF ENDOCRINE DISEASE: A clinical update on tumor-induced hypoglycemia
Iglesias, P., & Díez, J. J. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-1012 · Cited by 158
Malignant transformation of a solitary fibrous tumor of the liver and intractable hypoglycemia
Chan, G., Horton, P. J., Thyssen, S. M., Lamarche, M., Nahal, A., Hill, D. J., Marliss, E. B., & Metrakos, P. P. (2007) · Journal of Hepato-Biliary-Pancreatic Surgery · doi:10.1007/s00534-007-1210-0 · Cited by 63
van Doorn, J. (2020) · BioFactors · doi:10.1002/biof.1623 · Cited by 41
“Another, sensitive, technique that has been successfully applied for the analysis of big IGFII in serum is Western immune blotting, using either antibodies directed against epitopes on mature IGF-II or the E-domain of pro-IGF-II.(39,93) Recently, although applied to dog serum, a promising parallel reaction monitoring-…”
MethodQiu, Q., Jiang, J.-Y., Bell, M. D., Tsang, B. K., & Gruslin, A. (2007) · Endocrinology · doi:10.1210/en.2007-0535 · Cited by 29
“patients (32), although it required 5 l sera and may not be”
BackgroundNon-islet-cell tumour hypoglycaemia (NICTH): About a series of 6 cases
Jannin, A., Espiard, S., Benomar, K., Cao, C. D., Mycinski, B., Porte, H., d’Herbomez, M., Penel, N., & Vantyghem, M. (2018) · Annales d Endocrinologie · doi:10.1016/j.ando.2018.01.005 · Cited by 19
Bokshan, S. L., Doyle, M. B., Becker, N., Nalbantoglu, I., & Chapman, W. C. (2012) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-012-1947-x · Cited by 17
Paraneoplastic hypoglycemia in a patient with a malignant solitary fibrous tumor
Mohammedi, K., Khalil, C. A., Olivier, S., Benabad, I., Roussel, R., & Marre, M. (2014) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-14-0026 · Cited by 16
Schovanek, J., Cibickova, L., Ctvrtlik, F., Tudos, Z., Karasek, D., Iacobone, M., & Frysak, Z. (2019) · Journal of Cancer · doi:10.7150/jca.30472 · Cited by 16
“Chromatography is considered as a gold standard for IGF-II measurement; however, the total levels of IGF-II might not be significantly changed, as explained above; rather, the ratio of produced “big” IGF-II/IGF-II might be of clinical importance, as might the ratio of IGF-I/IGF-II [29, 30].”
BackgroundIGF2-induced hypoglycemia unresponsive to everolimus
Korevaar, T. I. M., Ragazzoni, F., Weaver, A., Karavitaki, N., & Grossman, A. B. (2011) · QJM · doi:10.1093/qjmed/hcr249 · Cited by 14
Self-citationKhan, M. I., & Weinstock, R. S. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0974-2.00016-6 · Cited by 28
A Unique Case of IGF-2 Induced Hypoglycemia Associated with Hepatocellular Carcinoma
Rana, P., & Kim, B. S. (2019) · Case Reports in Endocrinology · doi:10.1155/2019/4601484 · Cited by 11
“Continued stimulation of insulin receptors suppresses free fatty acid release and inhibits gluconeogenesis, glycogenolysis, and ketogenesis by the liver, further exacerbating hypoglycemia [1, 2, 4].”
BackgroundInfluentialSevere Hypoglycemia Induced by IGF-II Producing Non-Islet Cell Tumor
Kanzaki, M., Kashihara, H., Kiura, K., Murakami, K., Iwagaki, H., Wada, J., & Makino, H. (2007) · Internal Medicine · doi:10.2169/internalmedicine.46.6455 · Cited by 9
Confirmed Hypoglycemia Without Whipple Triad: A Rare Case of Hyper-Warburgism
Goyal, I., Ogbuah, C., Chaudhuri, A., Quinn, T. D., & Sharma, R. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa182 · Cited by 9
“Big IGF-2 can be detected by radioimmunoassays using antibodies against the E-domain [18, 19] or thin-layer chromatography [20]; however, these assays are not readily available commercially.”
BackgroundA Rare Diagnosis After the Fall of a 96-Year-Old Woman: Doege-Potter Syndrome
Pincelli, A. I., Perotti, M., Massariello, F., Gatti, A., Calella, D., Cimino, V., Haas, J., Bellelli, G., Mazzola, P., & Annoni, G. (2018) · Current Aging Science · doi:10.2174/1874609812666181205142247 · Cited by 9
Doege-Potter syndrome due to a solitary fibrous tumor of the pleura: a case report
Estrada-Maya, J., Montejo, J. S., Baez, D. K., & Garzón, J. C. (2024) · Journal of Medical Case Reports · doi:10.1186/s13256-024-04658-1 · Cited by 7
“The relevance of prognostic biochemical, histological, and imaging parameters, such as IGF-2 levels, vimentin, CD34, bcl-2, or CD99 positivity but cytokeratin negativity, and tumor size > 10 cm, is unclear [13].”
BackgroundRefractory hypoglycemia in a patient with functional adrenal cortical carcinoma
Marchetti, K. R., Pereira, M. A. A., Lichtenstein, A., & de Paiva, E. F. (2016) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-16-0101 · Cited by 7
Mathez, A. L. G., Moroto, D., Dib, S. A., & de Sá, J. R. (2016) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-016-0148-2 · Cited by 5
“In patients with non-islet cell tumor the pool of bigIGF2 increases and 80 % of this molecule is bounded to IGFBP3 only, forming a lower molecular weight that crosses the endothelial barrier and acts on insulin receptors [4, 7, 20, 22].”
BackgroundCryer, P. E. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00034-1 · Cited by 7
Effective management of recurrent Doege–Potter syndrome with somatostatin‐analogues: A case report
Schöler, F., Storz, M. A., Khavaran, A., Hümmler, N., Russe, M. F., Wielenberg, C., Laubner, K., & Seufert, J. (2024) · Cancer Reports · doi:10.1002/cnr2.1992 · Cited by 4
“10,16 Complete resection or tumor debulking of the Big-IGF-II producing SFT is the most promising treatment for patients with DPS, particularly in light of the fact that the majority of metabolic alterations due to increased Big-IGF-II are fully reversible.”
BackgroundOutside the Thorax: Doege–Potter Syndrome Presenting as a Retroperitoneal Abdominal Mass
Berrebi, D., Symczyk, O., Cater, T. L. G., Adelanwa, A., Bacaj, P., Thomay, A. A., & Haider, A. (2021) · Case Reports in Endocrinology · doi:10.1155/2021/9919321 · Cited by 4
“Continued stimulation of insulin receptors by IGF-2 leads to further suppression of free fatty acid release as well as inhibition of gluconeogenesis, glycogenolysis, and ketogenesis by the liver [11, 12].”
BackgroundBertherat, J. Y. (2006) · EMC - Endocrinologie - Nutrition · doi:10.1016/s1155-1941(06)40974-4 · Cited by 4
Non-Islet Cell Tumor Hypoglycemia: A Rare Cause of Hypoglycemia in Pulmonary Sarcomatoid Cancer
Legare, T. B., Hamilton, O., Dhannoon, S. M., & Ali, S. K. (2017) · Cureus · doi:10.7759/cureus.1972 · Cited by 3
Retroperitoneal Doege–Potter syndrome with intraoperative blood glucose monitoring
Nagasaka, H., Suzuki, T., Kondo, T., Koizumi, M., Terao, H., Murohashi, Y., Okubo, Y., Yokose, T., & Kishida, T. (2024) · IJU Case Reports · doi:10.1002/iju5.12765 · Cited by 2
“9,10 In IGF-II-producing tumors, patients with metastatic disease, elevated serum lactate dehydrogenase activity, or tumors larger than 12 cm are more likely to produce more IGF-II and become hypoglycemic.”
BackgroundElsdai, I., & Elsdai, T. (2023) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000000537 · Cited by 2
ステロイドが有効であった Non-Islet Cell Tumor Hypoglycemia の1例
謙太郎, 井., Kanzaki, M., 裕一, 松., 寺見隆宏, 泉, 伊., 慶一, 藤., 寺見, 桃., 柏原宏美, 敏郎, 米., 淳, 和., et al. (2011) · 糖尿病 · doi:10.11213/tonyobyo.54.277 · Cited by 2
Koizumi, Y., Hiraoka, A., Michitaka, K., Tazuya, N., Ichiryu, M., Nakahara, H., Ochi, H., Tanabe, A., Hidaka, S., Kodama, A., et al. (2011) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-010-0200-y · Cited by 2
Cryer, P. E. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00034-4 · Cited by 5
Layman, P. F., Davis-Merritt, D., & Neff, P. (2020) · The Permanente Journal · doi:10.7812/tpp/19.142 · Cited by 1
Alletto, M., Burgio, A., Fulco, G., Geraci, G., Groppuso, C., Gruttadauria, G., Manfrè, E., Mastrosimone, G., Salvaggio, S., Urrico, G. S., et al. (2020) · Italian Journal of Medicine · doi:10.4081/itjm.2020.1276 · Cited by 1
Tumour-induced hypoglycaemia: a narrative review
Barber, T. M., Bannon, C. A. M., Weickert, M. O., Kyrou, I., & Randeva, H. S. (2021) · Journal of Laboratory and Precision Medicine · doi:10.21037/jlpm-20-110 · Cited by 1
“This provides an explanation for a raised IGF2-to-IGF1 ratio as a characteristic biochemical signature of NICTs [identifiable via thin-layer liquid chromatography mass spectroscopy (LC/MS)] (31).”
BackgroundThissen, J. (2007) · Springer eBooks · doi:10.1007/978-2-287-33475-7_15 · Cited by 2
Síndrome de Doege Potter y derrame pericárdico, como manifestaciones iniciales de neoplasia pulmonar
Carrillo, L., Camacho, I., & Flores, J. (2013) · Anales de la Facultad de Medicina · doi:10.15381/anales.v69i2.1152
Doumenc, B., & Zundel, J. (2009) · EMC - Urgenze · doi:10.1016/s1286-9341(09)70019-5
Mak, I. Y. F., & Grossman, A. B. (2022) · doi:10.1093/med/9780198870197.003.0112 · Cited by 1
Self-citationOrgiazzi, J. (2010) · Springer eBooks · doi:10.1007/978-2-287-72070-3_46
Doumenc, B., & Zundel, J. (2008) · EMC - Médecine d urgence · doi:10.1016/s1959-5182(08)73356-7
Zehra, K. A. R. A. (2023) · doi:10.59287/sbyc.573
Metadata
- Authors
- Miraki-Moud, F., Grossman, A. B., Besser, M., Monson, J. P., & Camacho-Hübner, C.
- Affiliations
- Department of Endocrinology, William Harvey Research Institute, Queen Mary University of London, London EC1M 6BQ, United Kingdom
- Queen Mary University of London (GB)
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2005-07-01
- Volume
- 90
- Issue
- 7
- Pages
- 3819-3823
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2171902529
- Semantic Scholar
- 04edda76952c221cd45d81153f532322c681cfa0
- Cited by
- 44
- References
- 27
- Citations by year
- 2024: 3 · 2023: 3 · 2022: 1 · 2021: 2 · 2020: 4 · 2019: 2 · 2018: 2 · 2017: 1 · 2016: 3 · 2015: 1 · 2014: 2 · 2013: 3 · 2012: 2
- FWCI
- 1.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- National Institute on Alcohol Abuse and Alcoholism (R37AA011408)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- non-islet cell tumor hypoglycemia, insulin-like growth factor II, Tricine-SDS-PAGE, immunoblot analysis, size exclusion chromatography, tumor markers, mesenchymal tumors, hypoglycemia
- MeSH terms
- Adult, Aged, Aged, 80 and over, Chromatography, Gel, Female, Humans, Hypoglycemia, Insulin-Like Growth Factor I, Insulin-Like Growth Factor II, Male, Middle Aged, Neoplasms, Protein Precursors, Blotting, Western
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.